Last reviewed · How we verify
NCT06955806
Clinical Efficacy and Molecular Dynamics of Quantum Molecular Resonance (QMR) Electrotherapy in Dry Eye Management
NA trial testing The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology in Dry Eye Disease (DED) in 30 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | The Hong Kong Polytechnic University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 31 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology
Conditions studied
- Dry Eye Disease (DED) — all drugs for Dry Eye Disease (DED) →
Sponsor
The Hong Kong Polytechnic University
Who can join
Adults 18 to 40, any sex, with Dry Eye Disease (DED). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to investigate the clinical efficacy and molecular mechanisms of Quantum Molecular Resonance (QMR) electrotherapy in the management of dry eye disease (DED). DED is a multifactorial condition characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities, leading to discomfort and visual disturbances. The Rexon-Eye device, which utilizes QMR technology, has shown positive effects in alleviating dry eye symptoms. However, the exact mechanisms by which the stimulation of high-frequency electrical fields promotes improvement in DED remain unclear. The research will be conducted as a longitudinal study involving 30 participants between the ages of 18 and 40 who meet the diagnostic criteria for DED. Participants will be randomly assigned to either a treatment group receiving QMR electrotherapy or a control group receiving a sham treatment, followed by a real treatment after second evaluation. Each participant in the treatment group will undergo a 20-minute weekly session for four weeks, with clinical evaluations and tear fluid collection occurring throughout the study. Comprehensive assessments will be performed to evaluate tear film stability, lipid layer composition, ocular surface health and corneal sensitivity. Tear samples collected during the study will undergo molecular analysis using mass spectrometry to identify biochemical changes associated with QMR electrotherapy. Additionally, safety evaluations will be conducted at each visit to monitor potential adverse effects. The study aims to determine whether QMR electrotherapy effectively improves clinical dry eye parameters while also uncovering the molecular changes in tear composition that may underlie its therapeutic effects. By exploring both clinical outcomes and biological mechanisms, this research will contribute valuable insights into the potential of QMR electrotherapy as an innovative treatment for dry eye disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06955806
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology
Trials testing the same drug.
- NCT07175909 — Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease · NA · recruiting
Other recruiting trials for Dry Eye Disease (DED)
Currently open trials in the same condition.
- NCT07243275 — SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease · Phase 4 · recruiting
- NCT07234318 — A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyc · active not recruiting
- NCT07396441 — Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye · Phase 4 · recruiting
- NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
- NCT06984549 — Telemedicine Evaluation of Dry Eye Disease Using a Portable Automatic Ocular Surface Imaging Device (PAOSID) · recruiting
Other The Hong Kong Polytechnic University trials
Trials by the same sponsor.
- NCT07505732 — Information-providing Chatbot · NA · not yet recruiting
- NCT07391449 — Heart Rate Variability Guided Physical Activity and Exercise Prescription in Individuals With Knee Osteoarthritis · NA · not yet recruiting
- NCT07450248 — The Use of Telephone-based ACT for Quitting Alcohol in the Young Population With Hazardous or Harmful Alcohol Use. · NA · not yet recruiting
- NCT07273682 — Nurse-led Transitional Care to Improve Symptom Management in Childhood Cancer Survivors · NA · not yet recruiting
- NCT07531082 — Effects of a Salutogenic Strength-based Social Robot-assisted Intervention on the Depressive Symptoms and Sense of Coher · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06955806 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hong Kong Polytechnic University
- Last refreshed: 12 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06955806.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing